Skip to main content

Table 1 The demographic details of the patients

From: Properties of oscillatory neuronal activity in the basal ganglia and thalamus in patients with Parkinson’s disease

Patient

Age/

gender

Disease duration

(years)

Motor

UPDRS

OFF/ON

Hoehn

Yahr Score

L-dopa equivalent

doses (mg/day)

Side of micro- electrode tract of nuclei

No. of neuron analyzed

4–5 Hz band oscillatory neuron(%)

βFB oscillatory neuron (%)

non-oscillatory neuron (%)

1

46/M

2

63.5/35.5

2.5

600

B-STN

2(28.6)

2(28.6)

3(42.9)

2

57/F

4

40/16.5

2.5

600

B-STN

6(85.7)

1(14.3)

0(0)

3

67/M

7

62.5/43

4

775

B-STN

6(54.5)

3(27.3)

2(18.2)

4

56/M

8

20/12

1.5

750

L-STN

3(42.9)

2(28.6)

2(28.6)

5

62/F

10

41.5/21

3

150

R-STN

4(80)

0(0)

1(20)

6

71/F

10

40/19

3

675

L-STN

2(33.3)

2(33.3)

2(33.3)

7

56/M

5

45/25.5

2.5

250

L-STN

3(37.5)

1(12.5)

4(50)

8

64/F

12

57.5/40

3

375

R-STN

4(50)

0(0)

4(50)

9

67/M

4

30/18.5

2.5

400

L(STN)

0(0)

2(50)

2(50)

10

66/F

7

61.5/31

3

600

B-STN

0(0)

9(90)

1(10)

11

68/M

4

52/26.5

2.5

675

B-STN

0(0)

0(0)

3(100)

12

61/F

5

44.5/24.5

2

300

L-GPi

1(14.3)

2(28.6)

4(57.1)

13

59/F

6

42.5/25.5

2.5

600

L-GPi

4(44.4)

2(22.2)

3(33.3)

14

57/M

6

56.5/32

3

600

R-GPi

8(66.7)

2(16.7)

2(16.7)

15

62/F

5

60/37.5

2.5

150

R-GPi

2(33.3)

2(33.3)

2(33.3)

16

51/F

7

52.5/26.5

2.5

400

L-GPi

3(30)

2(20)

5(50)

17

48/M

5

32.5/18

2.5

300

R-GPi

4(66.7)

1(16.7)

1(16.7)

18

58/M

10

59.5/33.5

4

600

L-GPi

1(20)

2(40)

2(40)

19

61/M

8

42/23.5

2.5

1200

L-GPi

0(0)

1(50)

1(50)

20

56/F

6

49/28

3

1800

R-GPi

0(0)

3(60)

2(40)

21

61/M

1

35/17.5

1.5

300

L-Vop/Vim

4(40)/3(30)

1(10)/1(10)

1(10)/0(0)

22

68/M

5

30/15.5

1.5

200

L-Vop/Vim

5(50)/0(0)

0(0)/0(0)

3(30)/2(20)

23

67/F

15

53/33

3

800

L-Vop/Vim

3(50)/3(50)

0(0)/0(0)

0(0)/0(0)

24

49/M

6

55/32

2.5

600

R-Vop/Vim

4(44.4)/4(44.4)

0(0)/0(0)

1(11.1)/0(0)

25

70/M

3

33/20

1.5

400

R-Vop/Vim

6(54.5)/1(9.1)

1(9.1)/1(9.1)

1(9.1)/1(9.1)

26

64/F

2

39.5/27.5

2.5

600

R-Vop/Vim

0(0)/2(100)

0(0)/0(0)

0(0)/0(0)

27

56/F

9

46.5/28.5

4

400

L-Vop/Vim

5(50)/3(30)

0(0)/1(10)

0(0)/1(10)

28

49/F

2

37.5/20.5

1.5

600

L-Vop/Vim

2(18.2)/5(45.5)

2(18.2)/1(9.1)

1(9.1)/0(0)

29

61/M

3

36.5/24

2.5

600

R-Vop/Vim

0(0)/0(0)

0(0)/0(0)

4(80)/1(20)

  1. Patients 1–11 belong to STN group, patients 12–20 belong to GPi group, patients 21–29 belong to Vop/Vim group; M, male; F, female; UPDRS, United Parkinson’s Disease Rating Scale; L-dopa equivalent daily doses (mg), calculated as sum of the dose of regular levodopa-benserazide or levodopa-carbidopa; B, Bilateral; L, Left; R, Right; No: number; βFB: β frequency band oscillatory neurons; STN: the subthalamic nucleus; GPi: the globus pallidus internus; Vop: the ventral oral posterior nucleus of thalamus; Vim: the ventral intermediate of thalamus